Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914869 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Potential of Mavorixafor
A Phase 1 study, sponsored by X4 Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT06914869 is a Phase 1 study that has completed, run by X4 Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT06914869, a Phase 1 study, has completed, sponsored by X4 Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Interventions
- DRUG Mavorixafor
- DRUG Carbamazepine
- DRUG Efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2025-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06914869
The ClinicalTrials.gov registry entry for NCT06914869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Mavorixafor is the first listed.
NCT06914869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06914869 about?
NCT06914869 is a clinical study titled "Drug-Drug Interaction Potential of Mavorixafor". The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
What is the current status of trial NCT06914869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-02-18. Estimated completion is 2025-05-19.
What interventions are being tested in trial NCT06914869?
The interventions under investigation include: Mavorixafor (DRUG), Carbamazepine (DRUG), Efavirenz (DRUG).
Who is sponsoring clinical trial NCT06914869?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.